💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains insteadUnlock them all

Philips Revises Annual Guidance After Q3 Profit Turnaround

Published 2023-10-23, 04:10 a/m
© Reuters.

Royal Philips, under the leadership of CEO Roy Jakobs, reported a notable turnaround in its third-quarter earnings today, reversing last year's losses. The Dutch health-tech firm revised its annual guidance upwards, now projecting a 6%-7% rise in comparable sales, an increase from an earlier forecast of mid-single-digit growth. This positive projection aligns with InvestingPro's data showing a 6.83% revenue growth for the company, and a recent acceleration in revenue growth as noted in InvestingPro Tips.

The adjusted EBITA margin is now expected to be between 10%-11%, exceeding the previous high-single-digit estimate for 2023. Interestingly, despite this positive outlook, the company's P/E Ratio stands at -7.54, according to InvestingPro Data, which may suggest that the market has yet to fully factor in these improvements. The company's net profit for shareholders stood at €88 million ($107.1 million), a significant shift from a €1.33 billion loss the previous year. This aligns with an InvestingPro Tip that net income is expected to grow this year.

Sales saw an 11% increase to €4.47 billion, surpassing last year's €4.31 billion and beating the consensus estimate of €4.415 billion. This growth was driven by double-digit increases in the diagnosis & treatment and connected care segments, along with high-single-digit growth in the personal health segment. The company's position as a prominent player in the Healthcare Equipment and supplies industry, as pointed out by InvestingPro Tips, likely contributed to this performance.

The company also reported significant savings of €258 million in Q3 due to restructuring measures. Adjusted EBITA was €457 million, more than double the consensus estimate of €209 million, with an EBITA margin of 10.2%. This figure is significantly higher than the company's EBITDA of 431.03M USD, as reported by InvestingPro Data.

Jakobs noted progress in the ongoing Philips Respironics recall. Remediation for sleep-therapy devices is nearly complete, while ventilator remediation is still underway. It's worth noting that despite the company's progress, management has been aggressively buying back shares, a move that is often seen as a sign of confidence in the company's future prospects, as highlighted by InvestingPro Tips.

For more insights like these, consider subscribing to InvestingPro, which offers real-time metrics and valuable tips for numerous companies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.